ArticleProtein science : a publication of the Protein Society2025
Evaluating the protonation state of the catalytic Cys25 in cruzain cysteine protease: A target for Chagas disease.
Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cruzain (Cz), the major cysteine protease of Trypanosoma cruzi, the etiological agent of Chagas disease, employs Cys25 as its catalytic nucleophile, enabling peptide bond hydrolysis via nucleophilic attack on the carbonyl carbon of substrates. The pKa of Cys25 can be modulated by the local environment in the free enzyme or upon formation of pre-reactive complexes with substrates or inhibitors. Here, we employ molecular dynamics (MD) simulations, free energy calculations, and constant-pH simulations with explicit solvent to investigate the protonation state of Cys25 in the apoenzyme and in complexes with either a substrate mimic (Ac-Ala-Ala-Ala-Gly-Ala-OCH₃) or the covalent inhibitor K777 (N-methyl-piperazine-phenylalanyl-homophenylalanyl-vinylsulfone-phenyl). The simulations consistently support the presence of a neutral Cys25/His162 dyad across all states examined. Binding of either substrate or inhibitor reinforces a weak hydrogen bond between Cys25 and His162 but does not substantially perturb the dyad's protonation state. These findings suggest that cruzain's catalytic dyad remains predominantly neutral in the apo and bound forms, with the formation of a CysS
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.